- Global Operation
- Contract Manufacturing
Erlotinib, a tyrosin kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine. Erlotinib hydrochloride has the molecular formula C22H23N3O4.HCL and a molecular weight of 429.90. The molecule has a pka of 5.42 at 25 c.
- First-line treatment of patients with metastatic Non-Small Cell Lung cancer (NSCLC) whose tumors have Epidermal Growth Factor Receptor (EGFR) exon 19 deletions or exon 21 substitution mutations as detected.
- Maintenance treatment of patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum based first-line chemotherapy.
- Treatment of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.
- First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
Erlotin 100 tablet: Each commercial box contains 30 tablets in Alu-Alu blister pack.
Erlotin 150 tablet: Each commercial box contains 30 tablets in Alu-Alu blister pack.